期刊文献+

富马酸替诺福韦酯的合成工艺改进(英文) 被引量:3

Improved synthesis of tenofovir disoproxil fumarate
原文传递
导出
摘要 目的合成抗病毒药物富马酸替诺福韦酯并进行工艺改进。方法以亚磷酸二乙酯和多聚甲醛为原料,经缩合、酯化反应制得对甲苯磺酰氧甲基膦酸二乙酯(4);再以(S)-缩水甘油为起始物,经氢化还原、缩合反应制得(R)-碳酸丙烯酯(7),7与腺嘌呤反应合成(R)-9-(2-羟丙基)腺嘌呤(8),8经醚化、水解反应得到替诺福韦(10),再经氯甲基碳酸异丙酯酯化、与富马酸成盐得到目标化合物。结果与结论目标化合物的结构经MS、1H-NMR谱予以确证,该合成路线的总收率提高到30.4%(文献报道的最高收率为21%)。 A practical manufacturing process of tenofovir disoproxil fumarate (TDF) was studied and optimized. Diethyl p-toluenesulfonyloxymethylphosphonate was prepared by diethyl phosphite and paraformaldehyde condensing and esterifing with p-toluenesulfonyl chloride. (S)-glycidol was hydrogenated and condensed with diethyl carbonate to afford (R)-propylene carbonate, which was coupled with adenine to give (R)-9-(2-hydroxypropyl) adenine, then etherification and hydrolysis to afford tenofovir, followed by esterification with chloromethyl isopropyl carbonate, forming fumaric acid salt to crystallize TDF. The overall yield of TDF from adenine was improved to 30. 4%. The structure of the target compound was confirmed by MS and 1H-NMR.
出处 《中国药物化学杂志》 CAS CSCD 2013年第5期372-376,共5页 Chinese Journal of Medicinal Chemistry
关键词 富马酸替诺福韦酯 核苷逆转录酶抑制剂 合成 工艺改进 tenofovir disoproxil fumarate nucleoside analogue reverse transcriptase inhibitor synthesis process improvement
  • 相关文献

参考文献16

  • 1ARIMILLI M N, KIM C U, DOUGHERTY J, et al. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs[J]. Antiviral Chem Chemother, 1997, 8(6): 557-564.
  • 2FUNG H B, STONE E A, PIACENTI F J. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection[J]. Clin Ther, 2002, 24(10):1515-1548.
  • 3JENH A M, PHAM P A. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B[J]. Expert Rev Anti Infect Ther, 2010, 8(10):1079-1092.
  • 4FRIIS G J, BUNDGAARD H. Prodrugs of phosphates and phosphonates: novel lipophilic α-acyloxyalkyl ester derivatives of phosphate- or phosphonate containing drugs masking the negative charges of these groups[J]. Eur J Pharm Sci, 1996, 4(1):49-59.
  • 5JONES J, COLQUITT J, SHEPHERD J, et al. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection[J]. Health Technol Assess, 2010, 14 (Suppl. 1):23-30.
  • 6YENI P. Update on HAART in HIV[J]. J Hepatol, 2006, 44(Suppl. 1):S100-S103.
  • 7HOLY A, MASOJIDKOVA M. Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases. I. The stepwise approach[J]. Collect Czech Chem Commun, 1995, 60(7):1196-1212.
  • 8HOLY A, DVORAKOVA H, MASOJIDKOVA M. Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases. II. The synthon approach[J]. Collect Czech Chem Commun, 1995, 60(8):1390-1409.
  • 9LARROW J F, SCHAUS S E, JACOBSEN E N. Kinetic resolution of terminal expoxides via highly regioselective and enantioselective ring opening with TMSN3. An efficient, catalytic route to 1,2-amino alcohols[J]. J Am Chem Soc, 1996, 118(31):7420-7421.
  • 10SCHUTZE L M, CHAPMAN H H, DUBREE N J P, et al. Practical synthesis of the anti-HIV drug, PMPA[J]. Tetrahedron Lett, 1998, 39(14):1853-1856.

二级参考文献15

  • 1Arimilli MN,Cundy KC,Dougherty JP,et al.Nucleotide analogs:WO,9804569[P].1998-02-05.(CA 1998,128:140970).
  • 2Joel T.Preparing optically active adenine hydroxypropylene comprises heating adenine with (R) -propylene oxide or (S)-propylene oxide in presence of solid base mineral and in organic solvent medium:FR,2884823[P].2006-10-27.(CA 2006,145:438458).
  • 3Schultze LM,Chapman HH,Dubree NJP,et al.Practicalsynthesis of the anti-HIV drug,PMPA[J].Tetrahedron Lett,1998,39(14):1853-1856.
  • 4Ortmann R,Wiesner J,Reichenberg A,et al.Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity[J].Arch Pharm Chem Life Sci,2005,338 (7):305-314.
  • 5Barral K,Priet S,Sire J,et al.Synthesis,in vitro antiviral evaluation,and stability studies of novel α-boranonucleotide analogues of 9-[2-(phosphonomethoxy) ethyl] adenine and (R) -9-[2-(phosphonomethoxy) propyl] adenine[J].JMed Chem,2006,49 (26):7799-7806.
  • 6Becker MW,Chapman HH,Cihlar T.Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same:WO,0208241[P].2002-01-31.(CA 2002,136:118705).
  • 7Holy A,Dvorakova H,Declercq EDA,et al.Antiretroviral enantiomeric nucleotide analogs:WO,9403467[P].1994-02-17.(CA 1994,122:106401).
  • 8Rao VUM,Prasad VSR,Babu BR,et al.An Improved process for the preparation of tenofovir:WO,2008007392[P].2007-07-11.(CA2008,148:168505).
  • 9Munger JD,Rohloff JC.Nucleotide analog composition and synthesis method:WO,9905150[P].1999-02-04.(CA 1999,130:158419).
  • 10Schultze LM, Chapman HH, Dubree NJP,et al, Practical synthesis of the anti-HIV drug, PMPA[J]. Tetrahedron Lett, 1998,39 (14) :1 853 -1 856.

共引文献18

同被引文献6

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部